tbuckley/cabot-search huggingface dataset:
Abstract 18189: Focal Fibrosis and Diffuse Fibrosis Are Predictors of Positive Left Ventricular Remodeling in Patients With Non-Ischemic Cardiomyopathy
Authors: Teerapat Yingchoncharoen, Tomoko Negishi, Kazuaki Negishi, Zoran B Popovic, Neville Gai, W.h, Tang, Scott D Flamm, Deborah H Kwon
Journal: Circulation (2013)

Background: Prognostic value of myocardial fibrosis in patients with non-ischemic idiopathic cardiomyopathy (NICM) is not well-defined. We sought to assess the association of focal and diffuse myocardial fibrosis to left ventricular reversed remodeling. Methods: Patients with NICM who underwent cardiac MRI and baseline and subsequent follow-up echocardiographic were included in the study. Post-contrast T1 times were measured using Look-Locker gradient echo, and was adjusted for renal function, body size, gadolinium dose and delayed time after Gadolinium injection. Patients were followed over a median time of 29 months (20,37) to evaluate changes of left ventricular end-systolic volume index (LVESVi) over time. Linear Mixed Model was used to assess the relationship between the LVESVi during follow-up,T1 value, and delayed hyperenhancement (DHE). Results: A total of 103 patients (mean age 51±15 years, 62% male) were included in the analysis. Mean LVEF 32±10%, LVESVi 62±39 ml/m2, and T1 time 415+98. DHE was identified in 45 patients (44%). Age, LVEF and LVESVi in patients with DHE are not statistically different compared to patients without DHE. Patient with DHE were more likely to be male (32 vs 11, p=0.024) and had lower T1 time (381±104 Vs 440±87, p=0.003). Patients with focal DHE (n=45) had higher LVESVi at baseline and during follow-up, compared to the patients with no DHE (Δ= 11.3 ml/m2 SE 8.8 ml/2, p= 0.024) (Figure A). However, post T1 values of the myocardium without DHE were not associated with differences in LVESVi. In patients without DHE (n=58), T1 value &gt; 450 was associated with further reduction in LVESVi at the follow-up (Δ= 24.6 ml/m2 SE 14.6 ml/2, p= 0.048)(Figure B.) Conclusion: Presence of myocardial DHE, but not T1 value, is a marker of LV reversed remodeling in NICM patients. However, diffuse fibrosis predicts LV reversed remodling in patients without DHE.
Cover Image: Music box spines
Authors: R. Pirmez, C.T. Sodré
Journal: British Journal of Dermatology (2016)

Dear Editor, Spiny keratoderma of the palms and soles (SKPS) is characterized by palmoplantar filiform projections and comprises a group of conditions known as digitate keratoses. A recently proposed algorithm attempts to facilitate diagnosis of such disorders.1 SKPS may be familial or sporadic. Sporadic cases have been associated with malignancies and systemic illnesses. Cases with no known associations are described, but they may represent an early manifestation of an undetected condition.2 This image shows a 72‐year‐old man with a 5‐year history of SKPS preceding diagnosis of IgA multiple myeloma (see Fig. 1). Treatment of SKPS is generally ineffective.2 Our patient declined treatment.
Association of tumoral BRCA1, RRM1 and RRM2 mRNA expression levels with clinical responses to front-line docetaxel/gemcitabine (DG) chemotherapy in patients with non-small cell lung cancer (NSCLC)
Authors: C. Papadaki, M. Trypaki, A. Koutsopoulos, I. Boukovinas, D. Mavroudis, E. Stathopoulos, M. Sfakianaki, V. Georgoulias, J. Souglakos
Journal: Journal of Clinical Oncology (2008)

8112 Background: To investigate the prognostic and predictive value of tumoral BRCA1, RRM1 and RRM2 in clinical outcome of patients with NSCLC treated with the DG regimen. Methods: Tumor samples from 102 chemotherapy-naïve patients with locally advanced or metastatic NSCLC treated with the DG regimen as front-line chemotherapy were retrospectively analyzed. BRCA1, RRM1 and RRM2 mRNA levels were determined by quantitative real-time PCR in patients’ microdissected primary tumor cells. Results: Patients’ characteristics included median age 60 years, performance status 0–1 (WHO): 94%, male: 90%. Successful amplification could be performed in 98 (96%) patients for BRCA1, and 96 (94%) for both RRM1 and RRM2. Low tumoral levels of RRM2 mRNA were significantly associated with response to treatment (RR) (p<0.001), and time to tumor progression (TTP) (p=0.014) but not overall survival (OS) (p=0.274). Patients with high BRCA1 and low RRM1 expression (n=18) presented higher RR (p=0.034), TTP (p=0.026) and OS (p=0.025) compared with patients with low BRCA1 and high RRM1 expression (n=18). Moreover, patients with high BRCA1 and low RRM2 expression (n=31) presented higher RR (p<0.001) and TTP (p=0.041) but not OS (p=0.348) compared with patients with low BRCA1 and high RRM2 expression (n=32). Patients with both low RRM1 and RRM2 expression (n=29) had a significantly higher RR (p=0.001), TTP (p=0.002) and a trend for prolonged OS (p=0.06) compared to patients with both genes overexpressed. Finally, patients with high BRCA1 and low RRM1 and RRM2 expression (n=17) had significantly increased RR (p=0.007), TTP (p=0.003) but not OS (n=0.183) compared with patients with low BRCA1 and high RRM1 and RRM2 expression (n=14). Conclusions: Combined analysis of tumoral expression of BRCA1, RRM1 and RRM2 is potentially an important tool for the selection of individualized chemotherapy of patients with NSCLC and requires further assessment in prospective studies. No significant financial relationships to disclose.
Maintenance Strategy with Fluoropyrimidines (Fp) Plus Bevacizumab (Bev), Bev Alone or No Treatment, Following a 24-Week First-Line Induction with Fp, Oxaliplatin (Ox) and Bev for Patients with Metastatic Colorectal Cancer: Mature Data and Subgroup Analysis of the Aio Krk 0207 Phase III Study
Authors: S. Hegewisch-Becker, U. Graeven, C. Lerchenmüller, B. Killing, R. Depenbusch, C. Steffens, S. Al-Batran, T. Lange, G. Dietrich, J. Stoehlmacher, A. Tannapfel, A. Reinacher-Schick, J. Quidde, A. Hinke, D. Arnold, H. Schmoll
Journal: Annals of Oncology (2014)
Prognostic factors for response to second induction course in patients showing persistent disease after first course of standard induction chemotherapy for de novo acute myeloid leukemia (AML)
Authors: J. Lee, S. Sym, S. Choi, J. Lee, Y. Lee, M. Seol, S. Ryu, J. Lee, W. Kim, K. Lee
Journal: Journal of Clinical Oncology (2007)

7056 Background: Standard induction chemotherapy for AML consists of cytarabine plus daunorubicin or idarubicin (‘7+3' regimen). For patients showing persistent leukemia after first induction course (IND1) of the induction, usual practice is to give a second course (IND2) of similar regimen (‘7+3' or 5+2'). This strategy, however, has not been well evaluated. We investigated prognostic factors for response to IND2. Methods: We performed a retrospective study in 110 patients with de novo AML. All patients received cytarabine (100 or 200 mg/m 2 /d) for 7 days plus daunorubicin (45–60 mg/m 2 /d) or idarubicin (12 mg/m 2 /d) for 3 days as IND1. Patients who showed persistent leukemia after IND1 were given the same doses and drugs as ‘5+2’ (n = 85) or ‘7+3’ (n = 25) for IND2. We collected the clinico-pathologic data of the patients at diagnosis and at IND2, and analyzed prognostic factors for response to IND2. Results: Sixty-one (55.5%) of 110 patients, who received IND2, achieved complete remission (CR). The causes of treatment failure were resistant disease in 35, complication of aplasia in 8, and indeterminated in 6. Five-year probabilities of overall and relapse-free survival were 25% and 21%, respectively. Multivariate analysis demonstrated that cellularity at interim BM biopsy &gt; 30% ( p = 0.015), blast percentage at interim BM aspiration &gt; 30% ( p = 0.031), presence of circulating blasts at IND2 ( p = 0.011), and unfavorable chromosomal abnormalities ( p = 0.014) were independent risk factors for failure to induce CR. The CR rates were significantly different according to the number of the risk factors: 73% for 0–1 factor, 48% for 2 factors, and 11% for 3–4 factors ( p &lt; 0.001). Conclusions: We identified 4 independent poor risk factors for CR in patients who showed persistent disease after standard induction chemotherapy and who received similar second induction course. Other treatment strategies such as high-dose cytarabine rather than standard regimens seem to be needed for the patients with 3–4 risk factors before IND2. No significant financial relationships to disclose.
라미부딘 내성 만성 B형간염 환자에서 아데포비어 단독치료의 효과와 아데포비어에 대한 유전자형 내성의 발생 양상
Authors: Dae Sik Kwon, 윤기태, 배정호, 허정, Kim Gwang Ha, 강대환, 송근암, 조몽
Journal: Clinical and Molecular Hepatology (2008)

목적: 아데포비어(Adefovir dipivoxil, ADV)는 뉴클레오타이드 유사체로 야생형 B형간염바이러스(HBV)뿐만 아니라 라미부딘 내성 HBV 변이형도 억제한다. 라미부딘 내성 환자에서 아데포비어의 내성 발생률이 높다고 알려져 있지만 이에 대한 연구는 아직 부족하다. 본 연구에서는 라미부딘 내성 HBV 감염 환자를 대상으로 아데포비어를 투여할 때 치료효과 및 유전자형 내성의 발생 양상을 조사하고자 하였다. 대상 및 방법: 이 연구는 라미부딘 내성 만성 HBV감염 환자로 아데포비어 단독치료를 시행하였던 124명을 대상으로 하였다. 아데포비어의 치료효과로 누적 혈청 ALT 정상화율과 혈청 HBV DNA 감소 정도 및 일정 수준(검출역치 2×10(4) IU/mL와 2×10(2) IU/mL) 이하로 감소하는 환자의 누적 비율을 확인하였다. HBeAg 양성환자의 경우에는 누적 HBeAg 음전율 및 혈청전환율을 확인하였다. HBV 중합효소의 변이는 직접 염기서열 분석법을 이용하여 확인하였다. 결과: 누적 혈청 ALT 정상화율은 12개월 및 24개월째 각각 69.4%와 75.5%였다. 아데포비어 12개월 및 24개월 투여 후 혈청 HBV DNA가 2×10(4) IU/mL 이하로 감소한 환자는 각각 79.8%, 89.2%였으며, 2×10(2) IU/mL 이하로 감소한 환자는 44.2%, 59.0%였다. 아데포비어 단독투여 12개월 및 24개월째 혈청 HBV DNA는 각각 평균 3.24 및 3.04 log10IU/mL로 아데포비어 단독치료 전과 비교하여 의미 있게 감소하였다(P<0.001). 아데포비어 투여 12, 24개월 후 변이형 rtN236T는 각각 25%, 42%, rtA180T/V는 각각 64%, 83%였다. 결론: 라미부딘 내성 만성 HBV 감염 환자에서 아데포비어 치료는 효과적이었지만 HBV 역전사효소의 유전자형 내성 발생률이 높았다.
Breathlessness in an ex-miner: an unusual consideration
Authors: Amanda T Goodwin, Jillian Wall, Smitha Rajaram, Khaled Amsha, David G Kiely
Journal: Thorax (2016)

A 73-year-old retired miner, with 36 years ‘at the coal face’, presented with a 5-year history of exertional dyspnoea on climbing steep inclines. His medical history was limited to quiescent chronic lymphocytic lymphoma, for which he required no chemotherapy or radiotherapy and had annual haematology follow-up. He was a smoker, with a 15 pack-year history, and took no regular medications.

The patient had a widely split second heart sound, with accentuation of the pulmonary component, and bilateral intercostal bruits. Echocardiography demonstrated normal left sided chambers, moderate mitral and tricuspid regurgitation, and a raised estimated systolic pulmonary artery pressure of 80 mm Hg. Pulmonary function tests showed an obstructive pattern (FEV1 1.91 L (70% predicted), FVC 3.62 L (101%), FEV1/FVC ratio 53%), with a mildly reduced diffusion capacity (transfer coefficient (KCO) 0.86 mmol/min/KPa/L, 70% predicted). On the incremental shuttle walking test, his oxygen saturations dropped from …
Response to bortezomib (BOR) and bone metabolism in multiple myeloma patients
Authors: M. Zangari, D. L. Esseltine, K. Najarian, F. Elice, C.-K. Lee, S. Yaccoby, R. Thertulien, B. Barlogie, G. Tricot
Journal: Journal of Clinical Oncology (2005)

6536 Background: Evidence of osteoblastic activation was first observed at our Institution in patients with progressive multiple myeloma (MM) during treatment with bortezomib (VELCADE). Osteoblastic activation, based on isolated alkaline phosphatase (ALP) elevation (without alteration of other liver function tests) with a parallel increase in bone specific ALP and parathyroid hormone, was noted to be associated to response. ALP variation was subsequently assessed in 182 MM patients treated with BOR on the SUMMIT trial. A significant difference in isolated ALP elevation was observed in patients achieving ≥ PR (≥50% paraprotein reduction using EBMT criteria) compared to the other patients (P = 0.02). Methods: In this study we report ALP variation in 584 patients with normal liver function at baseline and treated in the randomized open label phase III APEX trial (Millennium protocol M34101–039). Patients with relapsed or progressive disease after at least one prior therapy were enrolled in the study, which compares time to disease progression in patients treated with BOR (1.3 mg/m2 on days 1, 4, 8, and 11 for up to eight 3-week cycles, followed by BOR on days 1, 8, 15 and 22 for up to three 5-week cycles) with those treated with high dose dex (dex 40 mg/day on days 1–4, 9–12 and 17–20 for up to four 5-week cycles, followed by dex on days 1–4 for up to five 4-week cycles). The Wilcoxon rank sum test was used to determine significant differences in ALP variation between the two groups. Results: The treatment arms involved 294 BOR patients and 290 dex patients. The two arms were comparable at baseline with regards to age, sex, isotype distribution, β2M, creatinine, LDH, AST, ALT and ALP. In the BOR arm, patients with ≥ PR (EBMT criteria) developed a statistically significant elevation of ALP compared to others at week 3 and 6 (P ≤ 0.02). No substantial changes in ALP level were observed in responders in the dex arm. Among all (BOR and dex treated) patients with ≥ PR, we observed within three months of therapy significantly higher ALP increases in the BOR arm (P ≤ 0.01). Conclusions: The results suggest that BOR promotes osteoblastic activation, which in turn appears to be associated with an anti-myeloma effect. This osteoblatic activity appears specific for BOR. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Millennium Millennium Millennium
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.
Authors: D B Geffen, R I Fisher, D L Longo, R C Young, V T DeVita
Journal: Journal of Clinical Oncology (1985)

Nine (5.1%) of 175 patients with advanced disseminated diffuse aggressive non-Hodgkin's lymphoma presented with renal involvement and were initially treated with combination chemotherapy alone. These patients were classified as having renal involvement based on histologic and radiographic criteria. Five of the nine patients presented with a serum creatinine level greater than 2.5 mg/dL. Four patients achieved a complete remission of all systemic disease. Eight patients had complete resolution of renal involvement. Two patients later had recurrent renal disease associated with other sites of recurrence. All five patients who presented with an elevated serum creatinine level recovered normal renal function; in fact, four patients had normal renal function by the end of the first cycle of therapy. No patient required hemodialysis. Only one patient remains alive and free of disease at 55 months; five patients have died with disseminated disease; two patients have died without evidence of disease; and one patient was lost to follow-up while in remission. Initial local control of renal involvement including normalization of renal function in diffuse aggressive lymphoma can be rapidly achieved by combination chemotherapy alone.
Bupropion in the tratment of sexual dysfunction in women diagnosed with breast cancer: An open-label, fixed dose study
Authors: C. Mathias, E. Moraes, C. Bastos, R. Athanazio, G. Nunez, L. Alban, I. Braghirolli, A. Del Giglio, E. Pondé, H. Moore
Journal: Journal of Clinical Oncology (2006)

6072 Background: Sexual morbidity after chemotherapy and hormonal therapy for breast cancer can seriously affect patients’ quality of life. Bupropion is an antidepressant that has been reported to increase libido. Objective: To investigate the improvement of sexual function in female breast cancer patients using bupropion. Methods: We performed an eight week open trial using bupropion in women diagnosed with breast cancer who had received chemotherapy and were currently receiving adjunctive hormonal therapy. The Arizona Sexual Experience Scale (ASEX) was used. The ASEX scale includes five questions that evaluate sexual function in the following areas: libido, excitability and ability to reach orgasm. Women received oral Bupropion 150mg/ daily for eight weeks and were evaluated prior to the initiation of the study and again during Weeks 4 and 8. Results: Twenty patients were included in the study. At the beginning of the study, the mean ASEX score was 23.45 [21.67–25.24] 95% CI. After four weeks of treatment, we observed a reduction in the mean ASEX score that persisted until the end of the study, at eight weeks: 18.45 [16.59–20.31] 95% CI, p = 0.0003) and 18.95 (SD ± 5.02 [16.60–21.30] 95% CI, p = 0.0024), respectively. Conclusions: In this non-controlled open trial bupropion 150 mg/daily was associated with improved sexual function in women receiving adjuvant systemic treatment for breast cancer. No significant financial relationships to disclose.
Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer.
Authors: M. Schirripa, F. Loupakis, C. Caparello, N. Funel, L. Pollina, E. Vasile, C. Cremolini, L. Salvatore, G. Masi, L. Fornaro, D. Campani, A. Falcone
Journal: Journal of Clinical Oncology (2011)

e14012 Background: Recent studies associated the histopathological response to chemotherapy with an improvement of prognosis for patient with colorectal liver metastases (CLM). An intensive treatment such as the FOLFOXIRI regimen produces a high rate of radiological and histopathologic responses. The contribution of bevacizumab added to chemotherapy in terms of tumoral shrinkage is a controversial issue, but it has been suggested that it might improve pathological regression of CLM. We investigated the effect of bevacizumab in addition to FOLFOXIRI on the pathologic response of CLM. Methods: Forty-two patients enrolled in phase II or III clinical studies investigating FOLFOXIRI/XELOXIRI (n=18) or FOLFOXIRI plus bevacizumab (n=24) who underwent secondary resection of liver metastases were selected on the basis of tissue samples availability. Pathologic response in terms of tumor regression grade (TRG), and toxicity in the surrounding normal liver tissue were assessed according to previously reported criteria (briefly, regression grading spans from TRG 1, indicating complete response and absence of tumor cells to TRG 5, indicating no response and abundance of tumor cells). TRG was correlated with outcome. Results: Fifteen (63%) of 24 patients treated with FOLFOXIRI plus bevacizumab showed a histopathological response (TRG 1, 2 or 3), while 5 (28%) of 18 patients treated with chemo-only showed a TRG 1, 2 or 3 (p= 0.03). No significant difference in terms of pCRs was detected (4/24 (17%) vs 2/18 (11%), p=0.69). The incidence of sinusoidal dilation and of liver steatosis was superimposable in the two groups. In the overall population (n=42), patients with TRG 1, 2 or 3 achieved a median PFS of 39.5 vs 15.7 months of patients with TRG 4 or 5 (HR=0.50, 95%CI 0.23-1.10, p=0.08). The same comparison restricted to patients treated with FOLFOXIRI plus bevacizumab produced a significant difference (37.5 vs 14.1 months, HR=0.29, 95%CI 0.06-0.82, p=0.02). Conclusions: The addition of bevacizumab to FOLFOXIRI improved pathologic response of CLM. TRG correlated with prognosis.
Low-dose oral etoposide: a new role for an old drug?
Authors: M L Slevin
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.10.1607 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2170588 Low-dose oral etoposide: a new role for an old drug? M L SlevinxM L SlevinSearch for articles by this author Show More St Bartholomew's Hospital, London, England. https://doi.org/10.1200/JCO.1990.8.10.1607 First Page PDF © 1990 by American Society of Clinical Oncology
Epidermal growth factor gene amplification is not frequent and cannot account for antitumor activity of cetuximab plus chemotherapy in advanced colorectal cancer patients
Authors: C. Garufi, M. Mottolese, A. Cianciulli, M. Zeuli, S. Buglioni, A. Torsello, B. Vanni, C. Campanella, R. Merola, E. Terzoli
Journal: Journal of Clinical Oncology (2006)

3561 Cetuximab has been shown to be active in the metastatic colorectal cancer, but EGFR detection by immunohistochemistry is not predictive for tumor response. Moroni et al (Lancet Oncology 2005) showed that, in patients responsive to Cetuximab, EGFR gene copy number, assessed by FISH, was increased. On this basis, copy number and protein status of EGFR were investigated in 70 primary and/or metastatic colorectal carcinomas. Protein expression was assessed by immunohistochemistry (IHC) using DAKO EGFRPharmDX kit. Gene and chromosome 7 copy numbers were identified by fluorescent in situ hybridization (FISH). Dual-target, dual-color FISH assays were performed using the LSI EGFR SpectrumOrange/CEP 7 Spectrum Green probe. EGFR gene copy number, chromosome 7 copy number and the average EGFR gene to chromosome 7 signal ratio were reported as FISH genetic variables. Chromosome 7 was polysomic when cancer cells showed multiple centromere signals: low polysomy (2 to 5 signals), high polysomy (&gt;5 signals). Samples with a ratio value ≥ 2.0 were considered to be amplified. EGFR protein was overexpressed in 57 out of 70 patients (81%). In the group of 58 patients evaluated as polysomic, 48 (82,7%) had a low polysomy level, whereas 20 (12.7%) had a high polysomy level. Gene amplification was seen only in 3/70 patients. High polysomy was evidenced only in the group of patients displaying an EGFR IHC score 2+/3+. Forty-six pretreated patients received a cetuximab-based treatment. Response to treatment has been already evaluated in 26 FISH-negative patients while for the other 20 it is still too early. We observed 7 PR (27%), 9 SD (35%) and 10 PD (38%). This study shows that in this series of advanced colorectal cancer patients, EGFR amplification, measured by FISH, is a rare event (4%) and could be considered together with chromosome 7 polysomy for the antitumor activity. No significant financial relationships to disclose.